Hormone replacement therapy and breast cancer

Maturitas

Volumn 34, Issue SUPPL. 2, 2000, Pages

  Marsden, Jo ^a  

^a REGIONAL CANCER CENTRE   (India)

Author keywords

Endogenous oestrogen; Progestin; SERM

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; PROGESTERONE; RALOXIFENE; SEX HORMONE BINDING GLOBULIN; TAMOXIFEN;

BREAST CANCER; BREAST DISEASE; CELL TRANSFORMATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ESTRADIOL BLOOD LEVEL; ESTROGEN DEFICIENCY; FAMILY HISTORY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAMMOGRAPHY; MORTALITY; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; REVIEW; RISK BENEFIT ANALYSIS; TUMOR GROWTH;

EID: 0033941658     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(00)00108-0     Document Type: Article

References (130)

1. Beatson GT. On the treatment of inoperable carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896;2:104-7.
2. Hulka BA, Stark AT. Breast cancer: cause and prevention. Lancet 1995;346:883-7.
3. Howell A, Clarke RB, Anderson E. Oestrogen, Beatson and endocrine therapy. Endocrine Rel Cancer 1997;4:371-80.
4. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996;348:1189-96.
5. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of randomised trials. Lancet 1998;351:1451-67.
6. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of randomised trials. Lancet 1998;352:930-42.
7. Ejlertsen B, Dombernowsky P, Mouridsen HT et al. Comparable effect of ovarian ablation (OA) and CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients (PRP). Proceedings of the (35th) Annual Meeting of the American Society of Clinical Oncology 1999;18:Abstract 248.
8. Davidson N, O'Neill A, Vukov A, et al. Effect of chemohormonal therapy in premenopausal, node ( + ), receptor ( + ) breast cancer: An Eastern Cooperative Oncology Group Phase III Intergroup Trial (E5188, INT-0101). Proceedings of the (35th) Annual Meeting of the American Society of Clinical Oncology 1999;18:Astract 249.
9. Jakesz R, Hausmaninger H, Samonigg H et al. Comaprison of adjuvant therapy with tamoxifen and goserilin vs CMF in premenopausal stage I and II hormone-responsive breast cancer patients: Four year results of Austrian Breast Cancer Study Group (ABCSG) Trial 5. Proceedings of the (35th) Annual Meeting of the American Society of Clinical Oncology 1999;18:Abstract 250.
10. Rutqvist LE. Zoladex and tamoxifen as adjuvant therapy in premenopausal breast cancer: A randomised trial by the Cancer Research Campaign (CRC) Breast Cancer Trials Group, the Stockholm Breast Cancer Study Group and the Gruppo Interdisciplinaire Valutazione Interventi in Oncologia (GIVIO). Proceedings of the (35th) Annual Meeting of the American Society of Clinical Oncology1999;18:Abstract 251.
11. Fisher B, Constatino JP, Wickerham Dl et al. and other National Surgical Adjuvant Breast and Bowel Project Investigators. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
12. Jordan VC, Glusman JE, Eckert S et al. Raloxifene reduces incident primary breast cancer: integrated data from multi-centre, double-blind, placebo-controlled, randomised trials in postmenopausal women. Br Cancer Res Treat 1998;50:Abstract 277
13. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995;87:190-7.
14. Berrino F, Muti P, Micheli A, et al. Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 1996;88:291-6.
15. Thomas HV, Key TJ, Allen D, et al. A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. Br J Cancer 1997;76:401-5.
16. Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid levels and risk of breast cancer in post-menopausal women. J Natl Cancer Inst 1998;90:1292-9.
17. Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR. Elevated serum estradiol and testosterone concentrations are assocaited with a high risk fro breast cancer. Ann Intern Med 1999;130:270-7.
18. Lønning PE, Helle SI, Johannessen DC, Ekse D, Adlercreutz H. Influence of plasma oestrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer. Br Cancer Res Treat 1996;39:335-41.
19. Whitehead MI, Godfree V. Types of HRT available. In: Whitehead MI, Godfree V, editors. HRT: Your Questions Answered. Edingburgh: Churchill Livingstone, 1992:93-122.
20. Thijssen JH, Blankenstein MA. Endogenous oestrogens and androgens in normal and malignant endometrial and mammary tissues. Eur J Cancer Clin Oncol 1989;25:1953-9.
21. Nachtigall MJ, Smilen SW, Nacthigall RD, Nachtigall RH, Nachtigall LE. Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy. Obstet Gynaecol 1992;80:827-30.
22. Taubes G. Epidemiology faces its limits. Science 1995;269:164-9.
23. Armstrong BK. Oestrogen therapy after the menopause: boon or bane? Med J Aust 1988;148:213-4.
24. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Int Med 1991;151:67-72.
25. Steinberg KK, Thacker SB, Smith JS, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. J Am Med Assoc 1991;265:1985-90.
26. Grady D, Ernster V. Invited commentary: does hormone replacement therapy cause breast cancer? Am J Epidemol 1991;134:1396-400.
27. Sillero-Arenas M, Delgado-Rodriguez M, Rodigues-Canteras R, Bueno-Cavanillas A, Galvez Vargas R. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynaecol 1992;79:286-94.
28. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiological studies. Am J Obs Gynaecol 1993;168:1473-80.
29. Collaborative Group on Hormonal Factors for Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis from 51 individual epidemiological studies. Lancet 1997;350:1047-60.
30. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999;91:1475-9.
31. Dupont WD, Page DL, Rogers LW, Parl FF. Influence of exogenous estrogens, proliferative breast disease and other variables on breast cancer risk. Cancer 1989;63:948-57.
32. Dupont WD, Page DL, Parl FF, et al. Estrogen replacement therapy in women with a history of proliferative breast disease. Cancer 1999;85:1277-83.
33. Cowan LD, Gordis L, Tonascia JA, Jones GS. Breast cancer incidence in women with progesterone deficiency. Am J Epidemol 1981;114:209-17.
34. Sainsbury R. Timing of surgery and the ovarian cycle. Endocr Rel Cancer 1997;4:251-4.
35. Pike MC, Bernstein L, Spicer DV. Exogenous hormones and breast cancer. In: Niederhuber JE, editor. Current Therapy in Oncology. St. Louis: CV Mosby, 1993:292-303.
36. Catherino WH, Jeng MH, Jordan VC. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Br J Cancer 1993;67:945-52.
37. Jeng M, Parker CJ, Jordan VC. Estrogenic potential in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res 1992;52:6539-46.
38. Campagnoli C, Biglia N, Peris C, Sismondi P. Potential impact on breast cancer risk of circulating insulin-like growth factor I modifications induced by oral HRT in menopause. Gynecol Endocr 1995;9:67-74.
39. Maudelonde T, Lavaud P, Salazar G, Laffargue F, Rochefort H. Progestin treatment depresses oestrogen receptor but not cathepsin D levels in needle aspirates of benign breast disease. Br Cancer Res Treat 1991;19:95-102.
40. Plu-Bureau G, Le MG, Sitruk-Ware R, Thalabard JC, Mauvais-Jarvis P. Progestin use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease. Br J Cancer 1994;70:270-7.
41. Anderson TJ. Effects on breast tissue of exogenous estrogen and progestogens. Acta Obstet Gynaecol Scand 1986;134 (Suppl):9-16.
42. Clarke CL, Sutherland R. Progestin regulation of cellular proliferation. Endocrine Rev 1990;11:266-301.
43. Musgrove EA, Sutherland RL. Steroids, growth factors and cell cycle controls in breast cancer. Breast Cancer Res Treat 1991;53:305-31.
44. Jones C, Ingram D, Mattes E, Hahnel R. The effect of hormone replacement therapy on prognostic indices in women with breast cancer. Med J Aust 1994;161:106-10.
45. Wren BG. Hormonal replacement therapy and breast cancer. Eur J Menopause 1995;2:13-21.
46. for the Nurses Health Study Research Group, Colditz GA, Rosner B. Use of estrogen plus progestin is associated with greater increase in breast cancer risk than estrogen alone. Am J Epidemol 1998;147 (Suppl):64S.
47. Persson I, Weiderpass E, Bergstrom R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement therapy. Cancer Causes Control 1999;10:253-60.
48. Magnusson C, Baron JA, Correia N, Bergstrom B, Adami HO. Breast cancer risk following long-term oestrogen and oestrogen-progestin replacement therapy. Int J Cancer 1999;81:339-44.
49. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. J Am Med Assoc 2000;283:485-91.
50. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy and breast cancer risk: estrogen versus estrogen plus progestin. JNCI 2000;92:328-32.
51. Goldzieher JW. Pharmacology of contraceptive steroids: a brief review. Am J Obstet Gynaecol 1989;160:1260-4.
52. Jung-Hoffman C, Fitzner M, Kuhl H. Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic properties. Hormone Res 1991;36:238-46.
53. Greendale GA, Reboussin BA, Sie A et al. for the Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med 1999;130:262-269.
54. Persson I, Thurfjell E, Holmberg LH. Effect of oestrogen and oestrogen-progestin replacement regimens on mammographic breast parenchymal density. J Clin Oncol 1997;15:3201-7.
55. Laya MB, Larson EB, Taplin SH, White E. Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. J Natl Cancer Inst 1997;88:643-9.
56. Byrne C, Schairer C, Wolfe J, et al. Mammographic features and breast cancer risk: effects with time, age and menopausal status. J Natl Cancer Inst 1995;87:1622-9.
57. Brisson L, Morrison AS, Khalid N. Mammographic parenchymal features and breast cancer in the breast cancer detection demonstration project. J Natl Cancer Inst 1988;130:1534-40.
58. Beral V, Banks G, Reeves G, Wallis M. Hormone replacement therapy and high incidence of breast cancer between mammographic screens. Lancet 1997;349:1103-4.
59. Harvey JA, Pinkerton JV, Herman CR. Short-term cessation of hormone replacement therapy and improvement of mammographic specificity. J Natl Cancer Inst 1997;89:1623-5.
60. Litherland JG, Evans AJ, Wilson AR. The effect of hormone replacement therapy on recall rate in the National Health Service Breast Screening Programme. Clin Radiol 1997;52:276-9.
61. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of oestrogen replacement therapy. Arch Int Med 1991;151:75-8.
62. Powles TJ, Hickish T. Breast cancer response to HRT withdrawal. Lancet 1995;345:1442.
63. Dhodapkar MV, Ingle JN, Ahmann DL. Estrogen replacement therapy withdrawal and regression of metastatic breast cancer. Cancer 1995;75:43-6.
64. Harvey SC, DiPiro PJ, Meyer JE. Marked regression of a nonpalpable breast cancer after cessation of HRT. Am J Roentgneol 1996;167:394-5.
65. Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin PM, Piana L. Clinical and biologic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynaecol 1995;85:11-7.
66. Markopoulous C, Berker U, Wilson P, Gazet JC, Coombes RC. Oestrogen receptor content of normal breast cells and breast carcinomas throughout the menstrual cycle. Br Med J 1988;296:1349-51.
67. Foidart JM, Colin C, Denoo X, Desreux J, Fournier S, de Linières B. Influence of percutaneous administration of estradiol and progesterone on the proliferation of human breast epithelial cells. In: Calvo F, Crépin M, Magdelenat H, editors. Breast Cancer, Advances in Biology and Therapuetics. John Libbey Eurotext©, 1996: 329-334.
68. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. NEJM 1997;336:1769-75.
69. Gambrell DR. Proposal to decrease the risk and improve the prognosis in breast cancer. Am J Obstet Gynaecol 1984;150:119-28.
70. Criqui MH, Suarez L, Barrett-Connor EL, McPhillips J, Wingard DL, Garland C. Postmenopausal estrogen use and mortality. Am J Epidemol 1988;128:606-14.
71. Berkqvist L, Adami HO, Persson I, Bergstrom R, Krusemo UB. Prognosis after breast cancer diagnosis in women exposed to oestrogen and oestrogen-progestogen replacement therapy. Am J Epidemol 1992;130:221-8.
72. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol 1990;97:1080-6.
73. Strickland DM, Gambrell RD, Butzin CA, Strickland K. The relationship between breast cancer survival and prior postmenopausal estrogen use. Obstet Gynaecol 1992;80:400-4.
74. Folsom AR, Mink PJ, Sellers TA, Hong CP, Zheing W, Potter JD. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Pub Health 1995;85:1128-32.
75. Persson I, Yuen J, Berqvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long-term follow-up of a Swedish cohort. Int J Cancer 1996;67:327-32.
76. Willis DB, Calle EE, Miracle-McMahill HL, Heath CW. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 1996;7:449-57.
77. Sellers TA, Mink PJ, Cerhan JR, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 1997;127:973-80.
78. Jernström H, Frenander J, Fernö M, Olsson H. Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients. Br J Cancer 1999;80:1453-8.
79. Schairer C, Gail M, Byrne C, et al. Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst 1999;91:264-70.
80. Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favourable histology. J Am Med Assoc 1999;281:2091-7.
81. Seeley T. Do women taking hormone replacement therapy have a higher uptake of screening mammograms? Maturitus 1994;19:93-6.
82. Canney PA, Hatton MQF. The prevalence of menopausal symptoms in patients treated for breast cancer. Clin Oncol 1994;6:297-9.
83. Couzi RJ, Helzlsouer KJ, Fetting JH. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol 1995;13:2737-44.
84. Carpenter JS, Andykowski MA, Cordova M, et al. Hot flashes in postmenopausal women treated for breast carcinoma. Cancer 1998;82:1682-91.
85. Zahasky KM, Loprinzi CL, Sloan J, Novotny PJ, Quella SK. Detailed prospective data regarding tamoxifen-induced hot flashes. Proceedings of the (35th) Annual Meeting of the American Society of Clinical Oncology 1999;19:Abstract 2283.
86. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17:2365-70.
87. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. NEJM 1994;331:347-52.
88. Rees CMP, Brockie JA, Suffling K, O'Byrne K, Harris A, Clarke PJ. Megestrol acetate to treat vasomotor symptoms. Proceedings of the 8th International Congress on the Menopause, Sydney, Australia 3rd-7th Novenber 1996, Maturitas 1997;Suppl 1:Abstract 233.
89. Milner M, Sinnott M, Gasparao D, Kelly A, Carole BK, Harrison R. Climacteric symptoms, gonadotrophins, sex steroids and binding proteins with conjugated equine estrogen-progestin and tibolone over two years. Menopause: J N Am Menopause Soc 1996;4:208-13.
90. Quella SK, Loprinzi CL, Sloan JA, et al. Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer 1998;82:1784-8.
91. Chenoy R, Hussain S, Tayob V, O'Brien PMS, Moss MY, Morse PF. Effect of oral gamolenic acid for evening primrose oil on menopausal flushing. Br Med J 1992;308:501-3.
92. Barton DL, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 1998;16:495-500.
93. Goldberg RM, Loprinzi CL, O'Fallon JR, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994;12:155-8.
94. Quella SK, Loprinzi CL, Barton D et al. Evaluation of soy phytoestrogens for treatment of hot flashes in breast cancer survivors: an NCCTG trial. Proceedings of the (35th) Annual Meeting of the American Society of Clinical Oncology 1999;19:Abstract 2285.
95. Loprinzi CL, Pisnansky TM, Fonseca R, et al. Pilot evaluation of venlaflexine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998;16:2377-81.
96. Ernst E. Herbal remedies as a treatment of some frequent symptoms during menopause. J Br Menopause Soc 1999;5:117-20.
97. Cheblowski RT, Collyar DE, Somerfield MR, Pfister D for the American Society of Clinical Oncology Working Group on Breast Cancer Risk Reduction Strategies. Tamoxifen and Raloxifene, J Clin Oncol 1999;17:1939-1955.
98. Carter AC, Sedransk N, Kelley RM, et al. Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. J Am Med Assoc 1977;237:2079-85.
99. Sutton R, Buzdar AV, Hortobagyi GN. Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer 1990;65:847-50.
100. von Scholtz E, Johansson H, Wilking N, Rutqvist LE. Influence of prior and subsequent pregnancy on breast cancer prognosis. J Clin Oncol 1995;13:430-4.
101. Yasamura T, Akami T, Mitsou M, et al. The effect of adjuvant therapy with or without tamoxifen on the endocrine function of patients with breast cancer. Jpn J Surg 1990;20:369-75.
102. Horn Y, Walach N, Pavlotsky A, Barak F, Benz C. Randomised study comparing chemotherapy with and without estrogen priming in advanced breast cancer. Int J Oncol 1994;4:499-501.
103. Hug V, Clark J, Johnson D. The results of modified use of chemotherapy for patients with metastatic breast cancer. Eur J Cancer 1994;30A:438-42.
104. Spicer DV, Pike MC, Rude R, Shoupe D, Richardson J. Pilot trial of a gonadotrophin hormone agonist with replacement hormones as a prototype to prevent breast cancer. Contraception 1993;47:427-44.
105. Stoll BA. Hormone replacement therapy in women treated for breast cancer. Eur J Cancer Clin Oncol 1989;25:1909-13.
106. Wile AG, Opfell RW, Margileth DA. Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 1993;165:372-5.
107. DiSaia PJ, Odicino F, Grosen EA, Cowan B, Peconelli S, Wile AG. Hormone replacement therapy in breast cancer. Lancet 1993;342:1232.
108. Powles TP, Casey S, O'Brien M, Hickish T. Hormone replacement after breast cancer. Lancet 1993;342:60-1.
109. Eden JA, Bush T, Nand S, Wren BG. A case-controlled study of combined continuous oestrogen-progestogen replacement therapy amongst women with a personal history of breast cancer. Menopause: J N Am Menopause Soc 1995;2:67-72.
110. Vassilopoulou-Sellin R, Theriault R, Klein MJ. Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer. Proceedings of the (32nd) Annual Meeing of the American Society of Clinical Oncology 1996;15:Abstract 50.
111. Peters GN, Jones SE. Estrogen replacement therapy in breast cancer patients: a time for change. Proceedings of the (32nd) Annual Meeting of the American Society of Clinical Oncology 1996;15:Abstract 148.
112. Decker D, Cox T, Burdakin J, Jaiyesimi I, Pettinga J, Benitez P. Hormone replacement therapy (HRT) in breast cancer survivors. Proceedings of the (32nd) Annual Meeting of the American Society of Clinical Oncology 1996;15:Abstract 209.
113. Bluming AZ, Waisman JR, Dosik GM et al. Hormone replacement therapy in women with previously treated primary breast cancer. Proceedings of the (35th) Annual Meeting of the American Society of Clinical Oncology 1999;18:Abstract 471.
114. Espie M, Gorins A, Perret F et al. Hormone replacement therapy (HRT) in patients treated for breast cancer: analysis of a cohort of 120 patients. Proceedings of the (35th) Annual Meeting of the American Society of Clinical Oncology 1999;18:Abstract 2262.
115. Natrajan PK, Soumakis K, Gambrell D. Estrogen replacement therapy in women with previous breast cancer. Am J Obstet Gynecol 1999;181:288-95.
116. Uršic-Vršcaj M, Bebar S. A case-control study of hormone replacement therapy after primary surgical breast cancer treatment. Eur J Surg Oncol 1999;25:146-51.
117. Consensus Statement, Treatment of estrogen deficiency symptoms in women surviving breast cancer. J Clin Endocrin Metab 1998;83:1993-2000.
118. Powles TJ, Eeles R, Ashley S, et al. Interim analysis of breast cancer in The Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98-101.
119. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998;352:93-7.
120. Gradishar WJ, Jordan VC. Clinical potential of new antoestrogens. J Clin Oncol 1997;15:840-52.
121. Love RR, Cameron L, Connell BL, Levanthal H. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 1991;151:1842-7.
122. Chang J, Powles TJ, Ashley SE, et al. The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. Ann Oncol 1996;7:671-5.
123. Powles TJ, Jones AL, Ashley SE, et al. The Royal Marsden Hospital chemoprevention trial. Breast Cancer Res Treat 1994;31:73-82.
124. Powles TP, Hickish T, Kanis J, Tidy A, Ashley S. Effect of tamoxifen in bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996;14:78-84.
125. Chang J, Powles TJ, Ashley SE, Iveson T, Gregoary RK, Dowsett M. Variation in endometrial thickening in women with amenorrhoea. Br Cancer Res Treat 1998;48:81-5.
126. Mortimer JE, Boucher L, Baty J, Knapp DL, Ryan E, Rowland JH. Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol 1999;17:1488-92.
127. Decensi A, Robertson C, Rotmensz N, et al. Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Br J Cancer 1998;78:572-8.
128. Vassilopoulou-Sellin R, Zolinski C. Estrogen-replacement therapy in women with breast cancer: a survey of patient attitudes. Am J Med Sci 1992;304:145-9.
129. Ganz PA, Greendale G, Kahn B, O'Leary JF. Are breast cancer survivors (BCS) willing to take hormone replacement therapy (HRT)? Proceedings of the (32nd) Annual Meeting of the American Society of Clinical Oncology 1996;15:Abstract 102.
130. Marsden J, Sacks NPM, Baum M, A'Hern R, Whitehead MI. Are randomised trials of hormone replacement therapy in symptomatic breast cancer patients feasible? Fertil Steril 2000;73:292-9.